Back to results

Active, not recruitingPhase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

GSK Investigational Site

San Francisco, California, United States

+25 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2022-03-22
Enrollment: 152 participants
Sponsor: GlaxoSmithKline
Purpose: treatment

Locations (26)

GSK Investigational SiteSan Francisco, California, United States
GSK Investigational SiteCharlotte, North Carolina, United States
GSK Investigational SiteOklahoma City, Oklahoma, United States
GSK Investigational SitePhiladelphia, Pennsylvania, United States
GSK Investigational SiteDallas, Texas, United States
GSK Investigational SiteSan Antonio, Texas, United States
GSK Investigational SiteSalt Lake City, Utah, United States
GSK Investigational SiteNedlands, Western Australia, Australia
GSK Investigational SiteOttawa, Ontario, Canada
GSK Investigational SiteToronto, Ontario, Canada
GSK Investigational SiteChengdu, China
GSK Investigational SiteJinan, China
GSK Investigational SiteShanghai, China
GSK Investigational SiteWuhan, China
GSK Investigational SiteDijon, France
GSK Investigational SiteLille, France
GSK Investigational SiteChiba, Japan
GSK Investigational SiteTokyo, Japan
GSK Investigational SiteSeoul, South Korea
GSK Investigational SiteSeoul, South Korea
GSK Investigational SiteBarcelona, Spain
GSK Investigational SiteMadrid, Spain
GSK Investigational SiteMadrid, Spain
GSK Investigational SiteMálaga, Spain
GSK Investigational SiteManchester, United Kingdom
GSK Investigational SiteSutton, United Kingdom

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors — TrialFind